论文部分内容阅读
目的探讨伊托必利联合雷贝拉唑治疗反流性食管炎患者的临床效果。方法选取2014年1月至2015年1月沈阳市红十字会医院收治的110例反流性食管炎患者为研究对象,按照随机数字表法将其分为研究组与对照组,各55例。对照组患者给予雷贝拉唑,研究组患者在对照组基础上采用伊托必利进行治疗,比较两组患者治疗前后临床症状改善情况、临床治疗效果及胃镜检查结果改善情况。结果治疗后,研究组患者呕吐、胃灼热、胃胀、胸骨疼痛、反酸临床症状评分均明显低于对照组,差异均有统计学意义(均P<0.05);研究组患者治疗的总有效率明显高于对照组,差异有统计学意义(χ2=4.58,P<0.05);研究组患者胃镜检查结果改善率明显高于对照组,差异有统计学意义(χ~2=4.96,P<0.05)。结论伊托必利联合雷贝拉唑治疗反流性食管炎患者临床效果明显,能有效改善患者临床症状。
Objective To investigate the clinical effect of itopride combined with rabeprazole in the treatment of patients with reflux esophagitis. Methods A total of 110 patients with reflux esophagitis admitted from Shenyang Red Cross Hospital from January 2014 to January 2015 were selected as study subjects and divided into study group and control group according to the random number table method, each with 55 cases. The rabbits in the control group were given rabeprazole. Patients in the study group were treated with itopride on the basis of the control group. The improvement of clinical symptoms, clinical treatment and gastroscopy results were compared between the two groups before and after treatment. Results After treatment, the scores of vomiting, heartburn, bloating, sore thoracic pain and acid reflux clinical symptoms in study group were significantly lower than those in control group (all P <0.05). The study group patients had total (Χ2 = 4.58, P <0.05). The improvement rate of gastroscopy in study group was significantly higher than that in control group, the difference was statistically significant (χ ~ 2 = 4.96, P < 0.05). Conclusion Itopride combined with rabeprazole treatment of patients with reflux esophagitis clinical effect is obvious, can effectively improve the clinical symptoms of patients.